R&D News | pharmaphorum

News

Beacon debut sheds light on Syncona’s gene therapy plans

UK life sciences investor Syncona is bankrolling a new gene therapy company, Beacon Therapeutics, that emerged this morning with a pipeline headed by a therapy acquired fr

News

Novartis builds hefty IgAN pipeline with $3.5bn Chinook buy

Further evidence of big pharma’s return to M&A dealmaking in 2023 has come this morning from Novartis, which has just agreed a takeover of rival Chinook Therapeutics f

R&D

Headlines and hot topics from ASCO and BIO, with Jonah Comst...

This week, pharmaphorum editor-in-chief Jonah Comstock headed to not one, but two back-to-back events in the US.

News

FDA sets Dec deadline for Vertex, CRISPR sickle cell therapy

The FDA has started a priority review of Vertex Pharma and CRISPR Therapeutics’ exagamglogene autotemcel (exa-cel) in sickle cell disease (SCD), with a decision on approva

News

AstraZeneca inks $2bn Treg cell therapy deal with Quell

UK start-up Quell Therapeutics has secured a partnership with AstraZeneca focused on cell therapies for autoimmune diseases, with an $85 million upfront payment and which

News

Epistemic AI launches biomedical GPT at BIO

One of the most compelling things about artificial intelligence chat technologies like ChatGPT and AIChat is their ability to generate human-like responses - but that may

Beacon debut sheds light on Syncona’s gene therapy plans

Novartis builds hefty IgAN pipeline with $3.5bn Chinook buy

Headlines and hot topics from ASCO and BIO, with Jonah Comst...

FDA sets Dec deadline for Vertex, CRISPR sickle cell therapy

AstraZeneca inks $2bn Treg cell therapy deal with Quell

Epistemic AI launches biomedical GPT at BIO

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks